B/F/TAF FDC in HIV-1 Infected Virologically Suppressed Adolescents and Children



Status:Recruiting
Conditions:HIV / AIDS
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:2 - 17
Updated:3/23/2019
Start Date:September 21, 2016
End Date:November 2023
Contact:Gilead Study Team
Email:GS-US-380-1474@gilead.com

Use our guide to learn which trials are right for you!

A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children

Cohort 1 and 2:

The primary objectives of this study are:

Part A:

- To evaluate the steady state pharmacokinetics (PK) of bictegravir (BIC) and confirm the
dose of the bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed dose
combination (FDC) in HIV-1 infected, virologically suppressed adolescents (12 to < 18 years
of age) and children (6 to < 12 years of age)

Parts A and B:

- To evaluate the safety and tolerability of the adult strength B/F/TAF FDC through Week 24
in HIV-1 infected, virologically suppressed adolescents (12 to <18 years of age) and children
(6 to <12 years of age)

Cohort 3:

The primary objectives of this study are:

Part A:

- To evaluate the steady state PK of BIC and confirm the dose of B/F/TAF 30/120/15 mg FDC in
HIV-1 infected, virologically suppressed children ≥ 2 years of age weighing ≥ 14 to < 25 kg

Parts A and B:

- To evaluate the safety and tolerability of the low dose B/F/TAF FDC tablet through Week 24
in HIV-1 infected, virologically suppressed children ≥ 2 years of age weighing ≥ 14 to < 25
kg


Key Inclusion Criteria:

Cohort 1: HIV-1 infected adolescents (12 to < 18 years of age and screening weight ≥ 35 kg)
who are virologically suppressed for ≥ 6 months prior to screening.

Cohort 2: HIV-1 infected children (6 to < 12 years of age and screening weight ≥ 25 kg) who
are virologically suppressed for ≥ 6 months prior to screening.

Cohort 3: HIV-1 infected children (≥ 2 years of age and screening weight of ≥ 14 to < 25
kg) who are virologically suppressed for ≥ 6 months prior to screening.

- Documented plasma HIV-1 RNA < 50 copies/mL on a stable regimen (or undetectable HIV-1
RNA level according to the local assay being used if the limit of detection is ≥ 50
copies/mL) for ≥ 6 months preceding the Screening visit. Unconfirmed virologic
elevations of ≥ 50 copies/mL (transient detectable viremia, or "blip") prior to
screening are acceptable. If the lower limit of detection of the local HIV-1 RNA assay
is < 50 copies/mL (eg, < 20 copies/mL), the plasma HIV-1 RNA level cannot exceed 50
copies/mL on two consecutive HIV-1 RNA tests.

- Stable antiretroviral regimen of 2 nucleoside reverse transcriptase inhibitors (NRTIs)
in combination with a third agent for a minimum of 6 months prior to the screening
visit. Individuals undergoing dose modifications to their antiretroviral regimen for
growth or who are switching medication formulation(s) are considered to be on a stable
antiretroviral regimen.

- Estimated glomerular filtration rate (GFR) ≥ 90 mL/min/1.73 m^2 according to the
Schwartz Formula

- No documented or suspected resistance to emtricitabine (FTC), tenofovir (TFV), or
integrase strand transfer inhibitors (INSTIs) including, but not limited to, the
reverse transcriptase resistance mutations K65R and M184V/I

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
We found this trial at
10
sites
?
mi
from
Tampa, FL
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Bloemfontein,
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
?
mi
from
Memphis, TN
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials